Missouri Xolair Reaction Attorneys
Xolair
The FDA approved Xolair in 2003 to treat asthma in adults and adolescents (12 years of age and older) who previously tested positive for allergies which were not being controlled by breathing treatments. Genentech, the manufacturer of Xolair, failed to reveal the risk of anaphylaxis (a life-threatening allergic reaction).
On February 21, 2007, the FDA ordered a black box warning of anaphylaxis to the product label for Xolair (Omalizumab). Anaphylaxis may include trouble breathing, chest tightness, dizziness, fainting, itching and hives, and swelling of the mouth and throat.
The FDA has continued to receive reports of serious and life-threatening allergic reactions (anaphylaxis) in patients after treatment with Xolair. Typically, these reactions take place within two hours of receiving a Xolair subcutaneous injection but delayed anaphylaxis; with onset two to 24 hours or even longer after receiving Xolair treatment have also been reported. Additionally, anaphylaxis may occur even after only the first dose of Xolair and also after later doses even if the first dose caused no reaction. The symptoms and signs of anaphylaxis in these reported patients include bronchospasm, hypotension, syncope, urticaria, and angioedema of the throat or tongue.
Missouri Pharmaceutical Liability Law Firm
If you or a loved one have experienced anaphylaxis due to Xolair, or have losed a loved one due to a severe allergic reaction to Xolair, don't hesitate to contact the experienced St Louis allergic drug reaction attorneys at Page Law for a free evaluation of your case.
